The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?
about
Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)Non-steroidal anti-inflammatory drugs (NSAIDs) for axial spondyloarthritis (ankylosing spondylitis and non-radiographic axial spondyloarthritis)Classification criteria for spondyloarthropathiesPhysical activity assessment in patients with axial spondyloarthritis compared to healthy controls: a technology-based approachMucosal-associated invariant T cell is a potential marker to distinguish fibromyalgia syndrome from arthritisUsability of an innovative and interactive electronic system for collection of patient-reported data in axial spondyloarthritis: comparison with the traditional paper-administered format.Whole body MR imaging in ankylosing spondylitis: a descriptive pilot study in patients with suspected early and active confirmed ankylosing spondylitis.First signs and symptoms of spondyloarthritis--data from an inception cohort with a disease course of two years or less (REGISPONSER-Early)Screening and evaluating the mimic peptides as a useful serum biomarker of ankylosing spondylitis using a phage display technique.Ankylosing spondylitis in iran; late diagnosis and its causes.The performance of different classification criteria sets for spondyloarthritis in the worldwide ASAS-COMOSPA study.The Nonradiographic Axial Spondyloarthritis, the Radiographic Axial Spondyloarthritis, and Ankylosing Spondylitis: The Tangled Skein of Rheumatology.Killer cell immunoglobulin-like receptors in HLA-B27-associated acute anterior uveitis, with and without axial spondyloarthropathySpondyloarthritis: clinical suspicion, diagnosis, and sports.Insights in to the pathogenesis of axial spondyloarthropathy based on gene expression profiles.Early axial spondyloarthritis.Crossreactive autoantibodies directed against cutaneous and joint antigens are present in psoriatic arthritis.Diagnosis and management of ankylosing spondylitis.Infliximab: 12 years of experienceFirst update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis.Combining information obtained from magnetic resonance imaging and conventional radiographs to detect sacroiliitis in patients with recent onset inflammatory back painPerformance of various criteria sets in patients with inflammatory back pain of short duration; the Maastricht early spondyloarthritis clinicFat Metaplasia on Sacroiliac Joint Magnetic Resonance Imaging at Baseline Is Associated with Spinal Radiographic Progression in Patients with Axial Spondyloarthritis.Vasoactive Intestinal Peptide in Early Spondyloarthritis: Low Serum Levels as a Potential Biomarker for Disease SeverityBest practice in primary care pathology: review 6.Biomarkers for diagnosis, monitoring of progression, and treatment responses in ankylosing spondylitis and axial spondyloarthritis.LLLT for the management of patients with ankylosing spondylitis.Juvenile spondyloarthritis treatment recommendationsAnkylosing spondylitis: recent breakthroughs in diagnosis and treatmentA multicenter, open-label, efficacy, pharmacokinetic, and safety study of adalimumab in Japanese patients with ankylosing spondylitis.Performance of referral recommendations in patients with chronic back pain and suspected axial spondyloarthritis.Evaluation of low back pain in athletes.The effect of three years of TNFα blocking therapy on markers of bone turnover and their predictive value for treatment discontinuation in patients with ankylosing spondylitis: a prospective longitudinal observational cohort study.How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?Pharmaceutical Benefits Scheme criteria for the use of tumour necrosis factor-alpha inhibitors in the treatment of ankylosing spondylitis in Australia: are they evidence based?Inflammatory back pain: the United States perspective.Early diagnosis of spondyloarthritis.Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1).Serum levels of biomarkers of bone and cartilage destruction and new bone formation in different cohorts of patients with axial spondyloarthritis with and without tumor necrosis factor-alpha blocker treatment.Developments in the scientific and clinical understanding of the spondyloarthritides
P2860
Q24186403-FDFB3DA7-9297-4471-A018-E844D40DB725Q24201300-2774FD8B-B27B-418C-94F1-E772035540B7Q24617746-B38AD6B5-5EE5-4A18-BFA4-23060EFDBF0AQ28396710-75DC9CE1-99B8-4700-8EC0-A209B057E40EQ28545955-BC600E4A-7B65-432F-9FC4-EA34CD4E5E44Q30662141-23A790DC-6488-454F-83C4-2BE84FBED66DQ33275865-98A374E8-0C2A-4C9B-9F30-BC596C9F09B8Q33408102-4555873F-8539-4D38-947E-AFF60BE8E912Q33543195-D3EE8351-DDC2-4EDD-9C71-8322A92C61E6Q33640595-06CA1A99-C1EC-48BC-9E81-085F9AA1047FQ33696947-F29019B8-6CE2-4E0A-9548-F48B03B3B355Q33710428-855F25D3-B380-4617-B08B-E2026FA9FFA7Q33845247-8EC8038D-ECF6-4ED6-A64D-06B91026374CQ33968580-A2A42FC8-2BAD-4762-B4DC-2D40FF518D90Q34413267-A1FE721F-ABAD-41B5-A186-FC2BD082FCD7Q34505203-2171C6FF-5BB0-4490-821D-F8F58207F3F3Q34713185-94318ADF-1AFF-45E1-8BC3-6906F67407ACQ35039166-8E664721-662C-4CF4-B158-2EC2FBB0024AQ35070446-0A42153B-A876-4CAF-84F4-99BCF99391DBQ35636900-F7998412-AEF1-4EA3-94BB-9FD516D3E5E4Q35637185-3383D771-BE16-4D72-8E34-313C1488A27CQ35638281-F02C23AF-5333-4974-8C28-5F53B3D0ABC1Q35745265-A135EF17-CBB7-45FD-A2F0-9C797D26EBC5Q35768646-88DD5F39-6150-4D11-9A1B-FE2BCF49F31CQ35770502-1F25D5A4-2583-41BD-8F88-C92326A9513DQ35809286-76FBCCDC-8246-4307-BE07-4AF5B1883081Q35900547-D2FFD439-7CDF-4FE0-9766-A4DED90155FAQ36004879-6BB8EDC2-852D-46AE-9201-397EC9EF4098Q36143588-45732EE3-A43D-4C84-9206-30775A394B86Q36157440-D9A04ABB-5890-41B8-96CA-D643BD39A5D7Q36204136-7F81F351-2D3B-4CD1-B41F-F78DE611BBC6Q36242458-005F5CFB-A21F-44AC-ADDF-695D207279B0Q36245903-01F4A7F5-0020-4D8C-A415-E9E1173418C3Q36292652-30C224B4-1B8E-496E-BDF3-27182933CA25Q36393852-E69D8CC6-D325-4421-89AD-0710B6EE7EA1Q36411074-7452A468-8902-404E-AFB3-28C7A3823D80Q36611042-A8601867-CF7E-4E41-90D5-F403B1AF2A16Q36876679-828A264E-DAD4-4973-8EB7-B0680A07FB5EQ36993320-A043C498-A1BF-4FF6-91CF-F43DB49D92B2Q37207018-E943DD09-9FCA-49B9-B857-E014A8AE7B69
P2860
The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria?
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
The challenge of diagnosis and ...... itis: do we need new criteria?
@ast
The challenge of diagnosis and ...... itis: do we need new criteria?
@en
type
label
The challenge of diagnosis and ...... itis: do we need new criteria?
@ast
The challenge of diagnosis and ...... itis: do we need new criteria?
@en
prefLabel
The challenge of diagnosis and ...... itis: do we need new criteria?
@ast
The challenge of diagnosis and ...... itis: do we need new criteria?
@en
P2093
P2860
P356
P1476
The challenge of diagnosis and ...... itis: do we need new criteria?
@en
P2093
Joachim Sieper
Martin Rudwaleit
Muhammad A Khan
P2860
P304
P356
10.1002/ART.20990
P577
2005-04-01T00:00:00Z